Anti-Phospholipid Dot

Anti-phospholipid antibody syndrome (APS, APAS, anti-cardiolipin syndrome, Hughes syndrome) is an autoimmune disease, which includes clinical symptoms such as arterial and venous thrombosis, thrombocytopenia and recurrent fetal loss. Primary and secondary forms of APAS can be distinguished. In the primary form of APAS, antibodies against phospholipids are formed without any underlying disease presence. In the secondary form of APAS, the symptoms are associated with other autoimmune diseases, particularly systemic lupus erythematosus (SLE).

Traditionally, laboratory diagnosis of APAS has been based on the study of antibodies against cardiolipin and ß2-glycoprotein I. Where these tests give a negative result, the determination of other antibodies provides an alternative diagnosis method. In addition, specific antibody profiles are associated with clinical complications associated with APAS, and may allow the differentiation between asymptomatic antibody carriers.

More information can you find in our video presentation

The Anti-Phospholipid Dot is a membrane-based enzyme immunoassay for the determination of IgG or IgM antibodies against phospholipids and serum proteins.

The use of a novel hydrophobic membrane allows the optimal epitope configuration of the phospholipids, and thus gives the assay a high sensitivity and specificity.

Assay PrincipleLine immunoassay
Assay Size20 determinations
IndicationAnti-phospholipid syndrome
ParameterIgG or IgM antibodies against, cardiolipid, phosphatidic acid, phosphatidyl- choline, -ethanolamine, -glycerol, -inositol, -serine, annaxin V, ß2-Glycoprotein I, prothrombin
PreparationPatient samples diluted directly in the test
Incubation Times30 min RT - 15 min RT - 10 min RT in the dark
SubstrateTetramethylbenzidine (TMB) precipitate
Sample MaterialHuman serum or plasma

With the Anti-Phospholipid Dot, one analysis can provide an antibody profile for a patient with suspected autoimmune coagulation disorder. In comparison to the conventional determination of individual parameters with ELISA, a higher diagnostic sensitivity is given at a significantly lower cost.

  • The kit is designed for both manual processing, or processing on an open automated System.
  •  An adaption of this assay for the DotDiver® is also available.

Roggenbuck, D., Borghi, M.O., Somma, V., Büttner, Th., Schierack, P., Hanack, K., Grossi, C., Bodio, C., Macor, P., von Landenberg, P., Boccellato, F., Mahler, M., Meroni, P. L. Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers. Arthritis Research & Therapy (2016) 18:11; DOI 10.1186/s13075-016-1018-x.


Roggenbuck, D., Somma, V., Schierack, P., Borghi, M.O., Meroni, P.L. Autoantibody profiling in APS. Lupus 2014 Oct 23; (12):1262-4.


Egerer, K., Roggenbuck, D., Büttner, T., Lehmann, B., Kohn, A., von Landenberg, P., Hiemann, R., Feist, E., Burmester, G.R. & Dörner, T. Single-step autoantibody profiling in antiphospholipid syndrome using a multi-line dot assay. Arthritis Res Ther. 2011 Jul 21; 13(4): R118.